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Ultrasound (US) is the primary imaging study of most
women with pelvic symptoms and signs that suggest
a gynaecological cause, and for the majority it defines
the site and nature of any pelvic mass. The key clinical
questions are (a) is there a mass and is it uterine
or ovarian; (b) is it likely to account for the clinical
presentation; (c) does it need removing and (d) if so,
by simple resection or as part of cancer surgery? The
principal concern is for ovarian cancer, which typically
presents with advanced stage (FIGO III and IV) disease.
For these women US confirms the presence of a complex
adnexal mass, ascites and/or metastatic deposits in the
peritoneum or viscera.
When there are no features of peritoneal dissem-
ination, assessment of the pelvic mass relies upon
detailed morphological assessment using US, which
is more reliable than Doppler US measurements in
defining their nature. The early promise of Doppler
US has not been realised [1]. A variety of morpho-
logical scoring systems are described [2,3]. Another
scoring system combines US and CA-125 data to
produce the risk of malignancy index (RMI). There
is overlap in the scores of benign lesions such
as dermoid tumours, inflammatory masses and en-
dometriomas, which may be managed non-operatively,
and malignancy. For these indeterminate masses MR
imaging is superior to US in characterisation [4,5].
With MR imaging dermoid tumours or endometriomas
can be confidently characterised using fat suppression
sequences and by recognition of the appearances of
haemorrhage. The importance of MR imaging is in
averting unnecessary intervention for complex benign
lesions.
At other end of the spectrum, with overt and
disseminated malignancy there is little doubt about the
nature of the mass, and most women proceed to radical
cytoreductive surgery. For women unfit for or beyond
the scope of surgery, or with a history of a cancer
whose metastases may mimic ovarian cancer (e.g. breast
and GI tract), CT-guided biopsy provides a simple
alternative to limited surgery or laparoscopy for obtaining
a confident histological diagnosis [6]. Biopsy of omental
cake, peritoneal or adnexal mass is possible.
After surgery for ovarian cancer CT is widely used
for monitoring chemotherapy, but this stems more from
its use in clinical trials as a reproducible modality than
from any evidence base. Another situation in which
indeterminate lesions cause clinical concern is when
the baseline post-surgical pre-chemotherapy examination
reveals a pelvic mass but the surgeon reports complete
resection. Here, resolution of uncertainty should be in
the forum of a specialist multidisciplinary team meeting.
Imaging has a role when management options would
be altered by clarifying the nature of the mass. The
distinction to be made is between residual cancer and
a treatment complication [7]. The main imaging options
for further assessment are MR imaging to distinguish
haematoma from solid tumour and transvaginal US,
which allows aspiration if infection is a clinical
concern.
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